Bridgefront Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Bridgefront Capital’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20,528	Closed	-$619K	–	725
2025 Q1	$619K	Sell	20,528 -1,274	-6%	-$41.7K	0.18%	195
2024 Q4	$762K	Buy	21,802 +10,606	+95%	+$396K	0.26%	111
2024 Q3	$449K	Buy	11,196 +5,637	+101%	+$262K	0.17%	203
2024 Q2	$265K	Buy	+5,559	New	+$228K	0.11%	333
2023 Q4	–	Sell	-4,948	Closed	-$224K	–	461
2023 Q3	$224K	Buy	+4,948	New	+$204K	0.16%	296
2023 Q2	–	Sell	-7,056	Closed	-$252K	–	564
2023 Q1	$252K	Buy	+7,056	New	+$265K	0.15%	262
2021 Q2	–	Sell	-6,798	Closed	-$306K	–	748
2021 Q1	$306K	Buy	6,798 +1,094	+19%	+$61K	0.1%	421
2020 Q4	$323K	Buy	+5,704	New	+$284K	0.11%	354

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bridgefront Capital's IONS Position: Q2 2025 in Review

Bridgefront Capital sold out of Ionis Pharmaceuticals (IONS) in Q2 2025, closing a stake of 20,528 shares — an estimated $619K sold.

Bridgefront Capital first reported a position in IONS in Q4 2020 and held it in 8 quarters. The position peaked at $762K in Q4 2024. 362 funds tracked by Wall St. Rank hold IONS as of Q2 2025.

Bridgefront Capital reported no remaining Ionis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Bridgefront Capital sold 20,528 Ionis Pharmaceuticals shares in Q2 2025, an estimated $619K.
Bridgefront Capital first reported a position in Ionis Pharmaceuticals in Q4 2020 and held it in 8 quarters.
Bridgefront Capital's Ionis Pharmaceuticals position peaked at $762K in Q4 2024.
362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2025.

Based on Bridgefront Capital's 13F filing for Q2 2025, filed 14 Aug 2025.